In animal models of lymphoma and solid tumors, the combination of PD-L1 blockade with ibrutinib increased the number of IFN-γ-producing, tumor-specific, central memory T cells and improved disease control in A20 lymphoma-bearing mice compared to mice treated with either ibrutinib or anti PD-L1 alone. This evidence concerns the gene CD274 and lymphoma.